HOME >> MEDICINE >> NEWS
Drug aimed at Huntington's eases chorea, the disease's hallmark feature

A drug widely available in Europe and Canada but not the United States dramatically eases one of the most disabling symptoms of Huntingtons disease, involuntary writhing movements known as chorea, according to a study in the Feb. 14 issue of the journal Neurology.

The medication, tetrabenazine, is currently being reviewed by the U.S. Food and Drug Administration. If approved, the medication would be the first authorized by the agency expressly for the treatment of Huntingtons disease, which affects about 30,000 people in the United States.

In a randomized, controlled study conducted in 84 patients at 16 sites around the nation, doctors found that the medication cut down involuntary movement on average by about 25 percent, with many patients experiencing a greater improvement. Overall, patients who received the medication were six times as likely to be considered by their doctors to have improved considerably, compared to participants who received a placebo.

Neuroleptic drugs like haloperidol (Haldol) are currently in widespread use in the United States to suppress chorea, but the effect of these drugs on chorea has never been studied in a systematic way, and they have a number of troublesome side effects, such as blunting of personality, loss of voluntary movement, and hindering balance. Our study showed that tetrabenazine, when appropriately dosed, can decrease chorea without causing those side effects, said Frederick J. Marshall, M.D., a neurologist at the University of Rochester Medical Center who led the study conducted by the Huntington Study Group. The study was funded by Prestwick Pharmaceuticals of Washington, D.C., the company that owns the rights to develop and sell the medication in the United States.

Tetrabenazine was originally developed in the 1950s to treat psychosis, but was quickly pushed aside by more effective medications. But doctors in the United Kingdom found it to be effective to treat the excessive involuntar
'"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
13-Feb-2006


Page: 1 2 3 4

Related medicine news :

1. Science of healthy foods subject of grant aimed at university students
2. Drug ads aimed at cancer patients difficult to read, make more appeals to effectiveness than safety
3. Cardiovascular flow disturbances study aimed at improving diagnosis and treatment
4. Endocrinologist-directed intervention aimed at primary care physicians improves diabetes care
5. New technology to speed up research into Huntingtons disease
6. Study identifies possible mechanism for brain damage in Huntingtons disease
7. Study identifies potential drug target for Huntingtons disease
8. Neural transplants provide persistent benefit in patients with Huntingtons disease
9. Rush designated Center of Excellence by Huntingtons Disease Society of America
10. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug aimed Huntington eases chorea the disease hallmark feature

(Date:11/24/2014)... Philadelphia, PA (PRWEB) November 24, 2014 ... care coordination and disease management services to health ... to implement Essette’s Medical Management software suite. ... SaaS platform in a program to reduce patients' ... includes Population Health Management, Care Management, Utilization Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
(Date:11/23/2014)... Tbdress.com has recently announced that ... Nov. 28, 2014. The special offer will provide ladies many ... one of the world’s largest women’s dresses retailers, and its ... can enjoy great discounts on that day: Everything at Tbdress.com ... (for orders above $89). , People can use the following ...
(Date:11/23/2014)... 23, 2014 (HealthDay News) -- The holidays can be ... sensory overload can trigger major meltdowns, an expert says. ... best of circumstances, but when you have children with ... an occupational therapy professor at University of the Sciences ... "It,s best to let your hosts or visitors know ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are popular ... its new collection of power suppliers. Additionally, it has ... suppliers. All the new models come with big discounts, ... Dec. 20, 2014. , SWAccessControl.com has thousands of happy ... for a long time. It is very wise to ...
Breaking Medicine News(10 mins):Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
(Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  GlySens ... two-year, two million dollar grant from the National Institute ... division of the National Institutes of Health (NIH).  The ... the GlySens second generation ICGM™ long term implantable glucose ... are underway, and enrollment is expected to begin before ...
(Date:11/24/2014)... DEVON, England , Nov. 24, 2014 /PRNewswire/ ... https://www.facebook.com/PifflersUnited announced the release of results ... pain therapy device, in the self-management of fibromyalgia ... the area of worst pain, very significant clinically ... The 140 group members with fibromyalgia used ...
(Date:11/23/2014)... Nov. 23, 2014  Aurobindo Pharma USA ... Capsules, USP 300 mg 100-count bottles to the consumer ... some empty capsules. Empty capsules could result ... consequences that could range from no effect, short term ... epilepticus (long period seizures) that could be life-threatening. Aurobindo ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
Cached News: